Abstract
Background: Efficient utilization of anticancer agents is crucial for effective malignancy treatment and cost management. WHO Prescribing Indicators provide a standardized measure for assessing drug usage. This study aimed to evaluate anticancer drug utilization patterns in a specialized oncology hospital using these indicators. Methods: A cross-sectional analysis involved reviewing medical records of anticancer drug prescriptions at a designated cancer treatment facility. Key WHO prescribing indicators, including drug per prescription average, proportions of anticancer drugs and generics usage, were assessed. Results: Analysis of 900 prescriptions revealed an average of 8.36 drugs per prescription, with 2.27 being anticancer drugs and 4.93 adjuvants. Notably, 71% of medications were prescribed generically and 85% were on the Essential Medicines List. Conclusions: This study highlights the value of WHO Prescribing Indicators in analysing anticancer drug utilization trends. Addressing prescribing deficiencies can refine treatment protocols, promote judicious pharmaceutical use and elevate patient care standards.
Introduction
Cancer treatment is notoriously complex and expensive, often requiring a "cocktail" of cytotoxic agents and supportive (adjuvant) drugs. In developing nations, "irrational" drug use—such as over-prescribing, using expensive brand names over generics, or ignoring standardized essential medicine lists—can lead to financial catastrophe for patients and increased risks of adverse drug reactions.
The authors address the lack of standardized data regarding how anticancer drugs are actually utilized in specialized clinical settings in Pakistan. By using the World Health Organization (WHO) prescribing indicators, they provide a measurable baseline to evaluate the rationality, safety, and cost-effectiveness of current oncological pharmacotherapy.
Methods
The researchers conducted a cross-sectional analysis of medical records at a specialized cancer facility in Peshawar.
- Sample Size: 900 prescriptions collected between January 2023 and December 2023, totaling 7,530 individual drug entries.
- Inclusion/Exclusion: The study included patients receiving anticancer therapy in day-care units and wards. It excluded pregnant patients, those receiving only supportive care, and those receiving only radiotherapy.
- Metrics: The study utilized WHO core prescribing indicators, including the average number of drugs per encounter, percentage of drugs prescribed by generic name, and percentage of drugs prescribed from the Essential Medicines List (EML).
Results
Disease Distribution and Demographics
The study found a notable female predominance (59% vs. 41% male), largely driven by the high prevalence of breast cancer, which accounted for 31.33% of all cases. The most affected age group was 51–60 years (24.8%). In terms of cancer categories, Carcinoma was the most prevalent (80.88%), followed by Sarcoma (7%) and Lymphoma (6.33%).
Prescribing Patterns and WHO Indicators
The analysis revealed a significant burden of polypharmacy, with an average of 8.36 drugs per prescription. This included an average of 2.27 anticancer drugs and 4.93 adjuvant drugs (such as anti-emetics and analgesics).
Regarding drug selection and naming, 85% of the prescribed drugs were on the Essential Medicines List. However, only 71% of medications were prescribed by their generic names. Additionally, 86% of the total drugs prescribed were injectables, reflecting the intensive clinical infrastructure required for chemotherapy.
Discussion and Conclusion
The high average of 8.36 drugs per prescription suggests a significant risk for drug-drug interactions and patient non-adherence due to regimen complexity. While EML adherence (85%) is relatively high, it falls short of the near-perfect adherence seen in similar studies in other regions. The gap in generic prescribing (71%) represents a critical opportunity to reduce the economic burden on patients.
In conclusion, this study highlights the value of WHO Prescribing Indicators in analyzing anticancer drug utilization trends. Addressing prescribing deficiencies—specifically by promoting generic drugs and managing polypharmacy—can refine treatment protocols and elevate patient care standards in specialized oncology settings.
Summary updated